Taraxerol
Taraxerol is a naturally occurring pentacyclic triterpenoid secondary metabolite found across a wide range of higher plant families. It has been extensively investigated for its medicinal and pharmacological properties, and various biotechnological approaches have been established to produce this compound using in vitro techniques. Over the past two decades, taraxerol has attracted sustained scientific interest for its anti-inflammatory, anticancer, antimicrobial, antidiabetic, and neuroprotective activities, all of which remain, as of this writing, at the preclinical stage with no registered clinical trials or approved human preparations.
Identity and Chemical Characterization
Nomenclature and Synonyms
Taraxerol, (3β)-D-Friedoolean-14-en-3-ol, is a pentacyclic triterpenoid. This compound is also known by a few other synonymous names, which are isoolean-14-en-3b-ol, skimmiol, alnulin, and tiliadin. Taraxerol was named "alnulin" when it was first isolated in 1923 from the bark of the grey alder (Alnus incana L.) by Zellner and Röglsperger. It also had the name "skimmiol" when Takeda and Yosiki isolated it from Skimmia (Rutaceae). The CAS registry number for taraxerol is 127-22-0.
Structural Chemistry
Its chemical structure was first elucidated by Beaton et al. (1955) who identified that the oleanane-3-ol lacks the methyl group at position 14, with an α-methyl substituent at position 13 and a double bond between positions 14 and 15. Taraxerol is a double-bond isomer of β-amyrin, another important naturally occurring triterpenoid in higher plants.
The molecular formula is C30H50O, and its molecular weight is 426.72. It is a colorless solid under room temperature with an estimated melting point of 283.50 °C and boiling point of 490.70 °C. It is practically insoluble in water and has a solubility of 9.552 × 10−5 mg/L estimated from the octanol-water partition coefficient. In practical laboratory settings, taraxerol appears as a white powder and is soluble in chloroform and methanol; it is insoluble in water.
The dominant stereoisomer found in biological systems is notable: taraxerol is an oleanan-3-ol with an alpha-methyl substituent at position 13, a missing methyl group at position 14, and a double bond between 14 and 15. The dominant biological stereoisomer in plant leaves and in sediments has the taraxer-14-en-3β-ol configuration.
A naturally occurring ester derivative, taraxerol acetate, is also widely studied. Taraxerol acetate is a COX-1 and COX-2 inhibitor with IC50 values of 116.3 μM and 94.7 μM, respectively.
Biosynthesis in Plants
Taraxerol is a pentacyclic triterpenoid that is actively produced by some higher plants as part of a defense mechanism. The biosynthesis of taraxerol in plants occurs through the mevalonate pathway in the cytosol, in which dimethylallyl diphosphate (DMAPP) and isopentyl pyrophosphate (IPP) are first produced, followed by squalene. Squalene is the primary precursor for the synthesis of triterpenoids, including taraxerol, β-amyrin, and lupeol, which are catalyzed by taraxerol synthase.
Natural Sources and Distribution
Plant Families and Species
Taraxerol can be extracted from various plant families and species found in nature. Members of the Asteraceae family comprise the greatest number of taraxerol-containing taxa, followed by the Euphorbiaceae and Malvaceae families. It should be noted that within the Euphorbiaceae family, species in the Euphorbia genus have shown considerable accumulation of taraxerol.
Among the best-documented sources:
- Taraxacum officinale (Asteraceae), Alnus glutinosa (Betulaceae), Litsea dealbata (Lauraceae), Skimmia spp. (Rutaceae), Dorstenia spp. (Moraceae), Maytenus spp. (Celastraceae), and Alchornea latifolia (Euphorbiaceae).
- Hypericum perforatum, Clitoria ternatea, Mangifera indica, and Strobilanthes crispus.
- Abroma augusta L. (Malvaceae) leaf, which is traditionally used to treat inflammatory disorders.
Documented yields vary by species and plant part; for example, Lannea schimperi stems, bark, and roots yield approximately 299 mg/kg dry weight, while Mangifera indica leaves yield a 0.4–0.9% yield.
Mangrove Ecosystems and Geochemical Role
Beyond its pharmacological significance, taraxerol serves an important role in paleoecology and geochemistry. Elevated taraxerol abundance is diagnostic of sediment accumulating in mangroves and taraxerol is particularly abundant beneath monospecific stands of Rhizophora spp. Taraxerol was undetectable in freshwater sediment. The carbon skeleton of taraxerol is stable and resistant to early diagenesis, enabling its prolonged persistence in sediments. Consequently, taraxerol holds considerable promise as a biomarker for tracing mangrove development. Considering the consistent salinity-dependent discrimination of 2H to salinity, and no significant diagenetic alteration of taraxerol δ2H values on centennial time scales, taraxerol H isotopes are a promising proxy for hydroclimate reconstruction in mangrove and mangrove-adjacent systems.
Traditional and Historical Use
Dandelion (Taraxacum officinale) in European and Asian Traditions
Dandelion (Taraxacum sect. Taraxacum, also referred to as Taraxacum officinale F.H. Wiggers coll.), a collective species of perennial herbaceous plants of the Asteraceae family, is commonly considered a weed; however, in the traditional societies of Central-Eastern Europe, it is a source of food and medicinal raw materials. The growing interest in the medicinal properties of herbal raw materials of dandelion encouraged researchers to focus on its use in traditional folk medicine of Central-Eastern European communities. Taraxerol is among the triterpenoid constituents present in the plant that contribute to these traditional applications.
The chemical composition of T. officinale includes phenolic compounds (polyphenolic acids, flavonoids, coumarins, tannins), sesquiterpene lactones (taraxacin, lactucopicrin, and cichorin, found mostly in the roots), triterpenes (α-amyrin, β-amyrin, lupeol, taraxol, taraxasterol), sterols (stigmasterol, β-sitosterol), polysaccharides (especially inulin in roots), minerals, amino acids, and vitamins.
T. officinale has important pharmacological effects: antioxidant (aqueous extracts), antihyperglycemic (ethanolic extracts of the root), cholagogue (methanolic extracts of leaves), diuretic (aqueous extracts), anti-inflammatory (methanolic extracts of flowers), immunomodulatory and anti-allergic (isolated compounds), anti-thrombotic (ethanolic extracts of the root), and prebiotic (aqueous extracts of the root).
Abroma augusta in Ayurvedic and Homeopathic Traditions
Abroma augusta (L.) L. f. has been used as traditional medicine by tribal women in India and Bangladesh from ancient times. Ayurvedic medicine, derived from herbal plants, has been used to reduce the adverse effects of synthetic drugs, and in homeopathy it has been used successfully for a long period. In India, the mother tincture of A. augusta is widely used in homeopathic medicine to treat uterine disorders and diabetes mellitus. Its root-bark is highly useful as a uterine tonic and is used to treat amenorrhoea and dysmenorrhea, with abortifacient and antifertility activities, whereas leaves are used for diabetes, rheumatic pains, gonorrhea, headache, and sinusitis. Taraxerol is specifically found in the leaves of this plant: leaves, reported to be useful in treating uterine disorders, contain taraxerol, its acetate, and lupeol.
Taraxacum mongolicum in Traditional Chinese Medicine
Modern pharmacological studies have shown that the traditional Chinese medicine (TCM) plant Taraxacum mongolicum possesses anti-cancer activity. Taraxerol (TRX) is a pentacyclic triterpene isolated from T. mongolicum, which is widely used in clinical treatment, and its anti-cancer effects have been extensively studied. It has been extensively applied to the clinical treatment of cancer; it effectively alleviates the adverse reactions caused by surgery and chemotherapy, as well as improves the tumor-related symptoms, immune functions, and quality of life. Previous studies have confirmed that Taraxacum mongolicum or its extracts exhibit various medicinal benefits, including diuretic, laxative, cholagogue, anti-rheumatic, anti-inflammatory, choleretic, anti-carcinogenic, and hypoglycemic activities.
Clitoria ternatea in South and Southeast Asian Traditions
Clitoria ternatea (butterfly pea), a perennial leguminous plant, has traditionally been employed in Ayurveda and folk medicine, and is increasingly recognized for its applications in functional foods, nutraceuticals, and as a natural colorant. Taraxerol is among its phytochemical constituents, identified and quantified from both natural and biotechnologically-derived root preparations.
Important note on traditional attribution: In all historical traditional uses described above, the medicinal applications were attributed to the whole plant or its crude extract, not to isolated taraxerol. Taraxerol's specific contribution to these traditional effects is a retrospective scientific inference, not a documented attribution from the traditions themselves.
Key Constituents and Established Mechanisms of Action
Anti-Inflammatory Mechanisms
Taraxerol is a pentacyclic triterpenoid found in medicinal plants, fruits, and vegetables, and is a potent anti-inflammatory agent. Its molecular mechanism of anti-inflammatory action involves interactions with many molecular targets, including NF-κB, MAPKs, and COX. The effects of taraxerol on oxidative stress, cell function, and inflammatory cell signaling have been comprehensively described.
The most detailed mechanistic picture has come from studies in macrophage cell lines. Taraxerol concentration-dependently inhibited inducible nitric-oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) at the protein and mRNA levels, and these inhibitions decreased the production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and IL-1β induced by LPS. Furthermore, taraxerol suppressed translocation of nuclear factor-κB (NF-κB), phosphorylation of IκBα, blocked IκBα degradation, and IKK and mitogen-activated protein kinase (MAPK) activation by inactivation of TGF-β-activated kinase-1 (TAK1) and Akt. In addition, taraxerol significantly inhibited the formation of TAK1/TAK-binding protein 1 (TAB1), which was accompanied by inducing degradation of TAK1, decreasing LPS-induced polyubiquitination of TAK1 as well as TAK1 phosphorylation.
Taraxerol is also known to augment the inhibitory effects of cyclooxygenases-1 and -2 by measuring prostaglandin E2 (PGE2) production, and induce quinone reductase in cultured Hepa1c1c7 mouse hepatoma cells.
Anticancer Mechanisms
In cancer biology, taraxerol exerts its effects through several interrelated pathways. In HeLa cervical cancer cells, taraxerol enhanced reactive oxygen species (ROS) levels and attenuated the mitochondrial membrane potential (ΔΨm) in HeLa cells. Taraxerol induced apoptosis mainly via the mitochondrial pathway, including the release of cytochrome c to the cytosol and activation of caspases 9 and 3, and anti-poly (ADP-ribose) polymerase (PARP). Taraxerol could induce the down-regulation of the anti-apoptotic protein Bcl-2 and up-regulation of pro-apoptotic protein Bax.
In gastric cancer, GO and KEGG enrichment analysis showed that steroid hormone receptor activity and the PI3K/AKT signaling pathway were the biological processes and pathways with the highest degree of enrichment. Additionally, cellular experiments revealed that taraxerol inhibited the proliferation, migration, and invasion of GC cells as well as induced G1 phase arrest and apoptosis in GC cells.
Taraxerol has shown in vitro cytotoxic activity against HepG2 and A431 human cancer cell lines and potent inhibition of topoisomerase II.
Neuroprotective and Cholinergic Mechanisms
Taraxerol is a triterpene that has been isolated from several plant species, and its various pharmacological properties have already been identified, including acetylcholinesterase (AChE) inhibition activity in vitro. Taraxerol suppresses the expression of proinflammatory mediators in macrophages by inhibiting the activation of the TAK1 and Akt proteins. This, in turn, prevents the activation of NF-κB, which would otherwise produce a variety of different proinflammatory mediators via a cascade effect. In addition, taraxerol has been shown to suppress the activity of acetylcholinesterase (AChE) in a dose-dependent way.
Antidiabetic Mechanisms
The compound was tested against protein tyrosine phosphatase 1B (PTP1B)—a negative regulator of the insulin-signalling pathway for the treatment of type 2 diabetes. Taraxerol was shown to exhibit moderate inhibitory properties against PTP1B at concentrations higher than 50 μM. Beyond PTP1B inhibition, taraxerol holds the potential to treat type 2 diabetes by dual action: as a glucose transport activator and as a glycogen synthesis stimulant. The authors also revealed that taraxerol could reverse the effects of dexamethasone-induced insulin resistance back to its normal homeostasis state.
Scientific Evidence by Area of Use
All current evidence for taraxerol is preclinical. No completed randomized controlled trials or peer-reviewed human clinical trials examining isolated taraxerol have been identified in the literature. The following summarizes the preclinical evidence base by therapeutic area.
Inflammation
In vivo animal evidence (moderate preclinical strength): A study by Khanra et al. examined the in vivo anti-inflammatory effect of taraxerol isolated from the methanol extract of Abroma augusta leaf. The anti-inflammatory effect of taraxerol at doses of 5 and 10 mg/kg (i.p.) was measured employing the carrageenan-induced paw edema model of acute inflammation. The carrageenan injection resulted in significant edema formation in the right paw. However, taraxerol (10 mg/kg) treatment could significantly (p < 0.05–0.01) attenuate carrageenan-induced paw edema 2 h onward. The effect of taraxerol at the dose of 5 mg/kg was found to be significant (p < 0.05) only after 4 h of carrageenan treatment.
In vitro mechanistic evidence: The mechanistic underpinning of this anti-inflammatory activity is well characterized in cell culture: taraxerol significantly inhibited lipopolysaccharide (LPS)-induced production of interleukin-1 (IL-1β), IL-6, and tumor necrosis factor-alpha (TNF-α) by interfering with the activation of TAK1 and Akt, thus preventing NF-κB activation. Taraxerol has also effectively inhibited NADPH oxidase (NOS) activity in murine microglial cells.
Evidence strength: Preclinical only. The molecular targets are well defined from multiple in vitro studies, and there is corroborating in vivo evidence from rodent models, but no human clinical data exist.
Cancer and Oncology
Gastric cancer (in vitro and network pharmacology): Research studies have indicated that taraxerol inhibits the growth of human gastric adenocarcinoma cells, induces apoptosis, and blocks the cell cycle in the G2/M phase. Additionally, taraxerol induced apoptosis of HeLa cells via the mitochondrial pathway. A network pharmacology study identified 135 potential targets for the treatment of gastric cancer, with the PI3K/AKT pathway being the most significantly enriched pathway, subsequently validated in cellular assays.
Glioblastoma (in vitro and in vivo xenograft): The aim of one study was to investigate the in vitro and in vivo anticancer and apoptotic effects of taraxerol acetate in U87 human glioblastoma cells. The effects on cell cycle phase distribution, cell cycle-associated proteins, autophagy, DNA fragmentation, and cell migration were assessed. The results demonstrated that taraxerol acetate induced dose- and time-dependent cytotoxic effects in the U87 cells. The study demonstrated that taraxerol acetate induces potent anticancer effects in U87 cells in in vitro and in vivo experiments, mediated via the induction of apoptosis, autophagy, cell cycle arrest, and inhibition of cell migration. Thus, taraxerol acetate may be a possible therapeutic agent against glioblastoma; however, further studies are required to decipher the exact mechanism of action and the toxicity profile of the compound.
Cervical cancer (in vitro): In HeLa cells, taraxerol induced apoptosis via the intrinsic mitochondrial pathway, involving cytochrome c release, caspase 9 and 3 activation, Bcl-2 downregulation, and Bax upregulation, as described above.
Tumor promotion inhibition (animal): Taraxerol remarkably inhibited TPA-induced tumor promotion on mouse spontaneous mammary tumors. Additionally, taraxerol exhibits cytotoxicity against sarcoma 180 cells and spontaneous mammary tumours in mice.
Evidence strength: Preclinical only. Evidence spans multiple cancer cell types and includes some in vivo xenograft data for the acetate derivative, but no human data. The findings are hypothesis-generating rather than clinically actionable.
Neurological — Alzheimer's Disease
Animal model evidence: Alzheimer's disease (AD) is a neurodegenerative disorder associated with cognitive impairment and cholinergic neuronal death. The use of medicinal plants as an alternative form of prevention or treatment of AD is an interesting area of research, since the standard drugs have many side effects. Taraxerol is a triterpene that has been isolated from several plant species, and its various pharmacological properties have already been identified, including acetylcholinesterase (AChE) inhibition activity in vitro. There is a lack of information in literature that confirms the effect of taraxerol in an animal AD-like model. One study assessed the effect of taraxerol on AChE activity in the animal's encephalon and hippocampus.
Taraxerol attracted wide interest among researchers due to its significant capabilities in modern pharmacology, including its potential in the treatment of Alzheimer's disease. The primary mechanistic basis for this interest is its in vitro AChE inhibitory activity and its capacity to suppress neuroinflammatory mediators (NO, PGE2, TNF-α, IL-6, IL-1β) via TAK1/Akt/NF-κB suppression.
Evidence strength: Early preclinical. AChE inhibition has been confirmed in vitro and explored in rodent models, but the evidence base for taraxerol specifically in AD is preliminary and limited. No human studies exist.
Diabetes and Metabolic Disease
Cell culture and in vitro enzyme studies: The antidiabetic mechanism of taraxerol has been explored from multiple angles. The antidiabetic properties of taraxerol were mostly attributed to its high affinity towards proteins involved in glucose metabolism. A study from 2010 demonstrated that taraxerol derived from Mangifera indica functions as a PI3K-dependent dual activator of glucose transport and glycogen synthesis in 3T3-L1 adipocytes. The reversal of dexamethasone-induced insulin resistance in adipocyte cultures has also been documented.
Evidence strength: Preclinical only (in vitro and cell-based). No in vivo animal diabetes models for isolated taraxerol and no human studies are available as of the most recent literature reviewed.
Cardiovascular / Cardioprotective Effects
Rodent model evidence: Researchers investigated the potential cardioprotective effects of taraxerol utilizing an isoproterenol (ISO)-induced cardiotoxicity model among Sprague Dawley rats. Specifically, subcutaneous tissue injections consisting of 5.25 mg/kg or 8.5 mg/kg ISO were administered over two consecutive days as stimuli to induce cardiac injury. To investigate the possibility of preventing damage caused by ISO-induced cardiotoxicity by taraxerol treatment, five groups were formed: a normal control group (1% Tween 80), an ISO control group, an amlodipine group administered 5 mg/kg/day, and various doses of taraxerol.
Pretreatment with taraxerol increased myocardial activity in SOD and GPx, leading to significant reductions in serum CK-MB levels along with MDA, TNF-α, and IL-6. Further histopathological analysis supported these observations, as treated animals had less cellular infiltration compared to untreated ones. These multifaceted findings suggest that oral administration of taraxerol could potentially protect hearts from ISO-caused damage by increasing endogenous antioxidant concentrations while decreasing pro-inflammatory cytokines.
Evidence strength: Single preclinical animal study. The findings are preliminary and require independent replication in additional animal models before human studies could be considered.
Antimicrobial Activity
Taraxerol has been documented to possess antimicrobial properties in multiple plant-based studies. Investigations of the minimum inhibitory concentrations (MICs) of taraxerol on several bacteria found that the compound is active against Gram-positive Bacillus subtilis and Staphylococcus aureus at a concentration of 15 [μg/mL in the source context]. Antimicrobial and anti-inflammatory activities of taraxerol have also been reported from triterpenoids of Strobilanthes callosus Nees, documented in the phytomedicine literature.
Evidence strength: Preclinical in vitro only. MIC data have been established but no animal infection models or clinical data are available for isolated taraxerol.
Body Systems and Health Areas Associated with Taraxerol
- Immune and inflammatory system: Inhibition of NF-κB, MAPK, JAK/STAT, and COX/LOX pathways; reduction of TNF-α, IL-6, and IL-1β in multiple model systems.
- Central nervous system: AChE inhibition (cholinergic pathway); neuroinflammation suppression relevant to neurodegeneration research.
- Oncology (preclinical): Cytotoxic activity against gastric, hepatocellular, cervical, glioblastoma, and mammary cancer cell lines via apoptotic and autophagic pathways.
- Endocrine and metabolic: Antidiabetic mechanisms including PI3K-dependent glucose transport activation and insulin sensitization in adipocyte models.
- Cardiovascular: Cardioprotective effects in isoproterenol-induced myocardial injury models, via antioxidant and anti-inflammatory action.
- Microbiology: In vitro activity against Gram-positive bacteria.
Dosage Forms and Dosages Reported in Studies
Taraxerol as an isolated compound has no established human clinical dose. The following are dosages used only in preclinical experimental research, exactly as reported in the primary literature:
- Anti-inflammatory (rodent, intraperitoneal): Taraxerol was administered at 5 and 10 mg/kg (i.p.) in the carrageenan-induced paw edema model.
- Cardioprotective (rodent, oral): When administered at doses of 20 mg/kg and 40 mg/kg, a significant reduction in cardiac biomarkers was observed while simultaneously increasing antioxidant activity.
- Cardioprotective comparison arm: An amlodipine comparison group was administered 5 mg/kg/day in the ISO-induced cardiotoxicity study.
- Antimicrobial (in vitro): Active against Gram-positive Bacillus subtilis and Staphylococcus aureus at 15 μg/mL MIC in laboratory assays.
- PTP1B inhibition (in vitro): Taraxerol was shown to exhibit moderate inhibitory properties against PTP1B at concentrations higher than 50 μM.
- COX inhibition (in vitro, taraxerol acetate): Taraxerol acetate is a COX-1 and COX-2 inhibitor with IC50 values of 116.3 μM and 94.7 μM, respectively.
No pharmacopeial monograph, WHO monograph, European Medicines Agency (EMA), EFSA, or NIH/ODS document has established a recommended human dose, a tolerable upper intake level, or an acceptable daily intake for isolated taraxerol.
Safety Considerations
Formal toxicological characterization of isolated taraxerol is limited in the published literature. The following points are derived from available preclinical and contextual evidence only:
- Absence of systemic toxicity studies: A review of taraxerol's anti-inflammatory properties explicitly addresses the limitations and obstacles in taraxerol research and highlights the need for additional research to completely understand the therapeutic potential and clinical applications of taraxerol in the treatment of inflammatory diseases. No peer-reviewed acute or chronic toxicity studies with established LD50 values for isolated taraxerol in mammals have been identified.
- Glioblastoma drug candidate caveat: Taraxerol acetate may be a possible therapeutic agent against glioblastoma; however, further studies are required in order to decipher the exact mechanism of action and the toxicity profile of the compound. This statement underscores the absence of a characterized safety profile even for the most advanced preclinical candidate.
- Water insolubility and bioavailability: Taraxerol is practically insoluble in water. This physicochemical property poses significant challenges for oral bioavailability in any eventual clinical application and has not been addressed in pharmacokinetic studies for isolated taraxerol found in the peer-reviewed literature.
- Traditional plant context: The plants from which taraxerol is primarily extracted, including Taraxacum officinale and Abroma augusta, have established traditional use records. However, effects and safety profiles of isolated compounds cannot be inferred from traditional whole-plant use. Abroma augusta is specifically noted in ethnopharmacological records for having abortifacient and antifertility activities in root-bark preparations, a consideration relevant to any extract-standardized preparation used in reproductive contexts.
- No known drug interactions: No peer-reviewed pharmacokinetic interaction studies between isolated taraxerol and pharmaceutical drugs have been identified in the sources reviewed.
- Research-use classification: Taraxerol is commercially available only as a research-grade chemical standard and is not listed on any regulatory body's positive list of dietary supplement ingredients with established safety review.
Research Gaps and Future Directions
Taraxerol has many important pharmacological actions including anti-cancer activity; its chemistry, biosynthesis aspects, and possible use as a drug in treatment of cancer are actively being reviewed in the literature. Despite a growing body of preclinical evidence, several critical gaps remain:
- No in vivo pharmacokinetic data (absorption, distribution, metabolism, excretion — ADME) for isolated taraxerol in any species.
- No dose-finding, dose-escalation, or Phase I clinical trial data in humans.
- No comparative effectiveness data against established therapeutic agents in equivalent disease models.
- Limited long-term or chronic-exposure toxicology data in animal models.
- Bioavailability enhancement strategies (nanoformulations, lipid-based delivery) remain largely unexplored in published research.
Taraxerol has been extensively investigated for its medicinal and pharmacological properties, and various biotechnological approaches have been established to produce this compound using in vitro techniques. Reviews provide in-depth summaries of the hypothesized taraxerol biosynthetic pathway, the medicinal properties of taraxerol, and recent developments on tissue culture for the in vitro production of taraxerol. The field is therefore at an active stage of compound production optimization preparatory to more advanced biological studies.
References
Go back